The administration of erythropoietin attenuates kidney injury induced by ischemia/reperfusion with increased activation of Wnt/β-catenin signaling

Journal of the Formosan Medical Association

Volumn 114, Issue 5, 2015, Pages 430-437

  Chen, Xiao ^a   Wang, Cen Cen ^a   Song, Shu Min ^a   Wei, Shi Yao ^a   Li, Jian Si ^a   Zhao, Shi Lei ^a   Li, Bing ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Erythropoietin; Kidney ischemia reperfusion injury; Micro RNA; Wnt catenin

Indexed keywords

BETA CATENIN; MICRORNA; MICRORNA 199A; MICRORNA 210; MICRORNA 214; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; WNT PROTEIN; ERYTHROPOIETIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; WNT SIGNALING PATHWAY; ACUTE KIDNEY INJURY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; KIDNEY; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; KIDNEY; MALE; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; WNT SIGNALING PATHWAY;

EID: 84930177865     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2015.01.007     Document Type: Article

References (43)

1. Nony P.A., Schnellmann R.G. Mechanisms of renal cell repair and regeneration after acute renal failure. J Pharmacol Exp Ther 2003, 304:905-912.
2. Lien Y.H., Lai L.W., Silva A.L. Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci 2003, 74:543-552.
3. Aydin Z., van Zonneveld A.J., de Fijter J.W., Rabelink T.J. New horizons in prevention and treatment of ischaemic injury to kidney transplants. Nephrol Dial Transplant 2007, 22:342-346.
4. Chang Y.T., Pan S.Y., Lin S.L. Seeking for a way to revive erythropoietin production in chronic kidney disease. J Formos Med Assoc 2013, 112:657-658.
5. Hu L., Yang C., Zhao T., Xu M., Tang Q., Yang B., et al. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 2012, 176:260-266.
6. Yeh P.Y., Liao F.L., Lin S.L. Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?. J Formos Med Assoc 2013, 112:655-656.
7. Nairz M., Sonnweber T., Schroll A., Theurl I., Weiss G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 2012, 14:238-246.
8. Simon F., Scheuerle A., Calzia E., Bassi G., Oter S., Duy C.N., et al. Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury. Crit Care Med 2008, 36:2143-2150.
9. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004, 15:2115-2124.
10. Furuichi K., Kaneko S., Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009, 13:9-14.
11. Namikoshi T., Satoh M., Horike H., Fujimoto S., Arakawa S., Sasaki T., et al. Implication of peritubular capillary loss and altered expression of vascular endothelial growth factor in IgA nephropathy. Nephron Physiol 2006, 102:9-16.
12. Ishii Y., Sawada T., Kubota K., Fuchinoue S., Teraoka S., Shimizu A. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 2005, 67:321-332.
13. Lin S.L., Li B., Rao S., Yeo E.J., Hudson T.E., Nowlin B.T., et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci USA 2010, 107:4194-4199.
14. Li B., Cohen A., Hudson T.E., Motlagh D., Amrani D.L., Duffield J.S. Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation 2010, 121:2211-2220.
15. Li B., Morioka T., Uchiyama M., Oite T. Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model. Kidney Int 2006, 69:323-330.
16. Kawakami T., Ren S., Duffield J.S. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol 2013, 229:221-231.
17. Saal S., Harvey S.J. MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens 2009, 18:317-323.
18. Chung A.C., Yu X., Lan H.Y. MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis 2013, 6:169-179.
19. Godwin J.G., Ge X., Stephan K., Jurisch A., Tullius S.G., Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci USA 2010, 107:14339-14344.
20. Rabb H., O'Meara Y.M., Maderna P., Coleman P., Brady H.R. Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997, 51:1463-1468.
21. Liu Y., Luo B., Han F., Li X., Xiong J., Jiang M., et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One 2014, 9:e90942.
22. Feng Q. Beyond erythropoiesis: the anti-inflammatory effects of erythropoietin. Cardiovasc Res 2006, 71:615-617.
23. Rossert J., Eckardt K.U. Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 2005, 20:1025-1028.
24. Ahmadiasl N., Banaei S., Alihemmati A., Baradaran B., Azimian E. The anti-inflammatory effect of erythropoietin and melatonin on renal ischemia reperfusion injury in male rats. Adv Pharm Bull 2014, 4:49-54.
25. Ahmadiasl N., Banaei S., Alihemati A., Baradaran B., Azimian E. Effect of a combined treatment with erythropoietin and melatonin on renal ischemia reperfusion injury in male rats. Clin Exp Nephrol 2014, 18:855-864.
26. Moeini M., Nematbakhsh M., Fazilati M., Talebi A., Pilehvarian A.A., Azarkish F., et al. Protective role of recombinant human erythropoietin in kidney and lung injury following renal bilateral ischemia-reperfusion in rat model. Int J Prev Med 2013, 4:648-655.
27. Caetano A.M., Vianna Filho P.T., Castiglia Y.M., Golim M.A., de Souza A.V., de Carvalho L.R., et al. Erythropoietin attenuates apoptosis after ischemia-reperfusion-induced renal injury in transiently hyperglycemic Wister rats. Transplant Proc 2011, 43:3618-3621.
28. Gobe G., Willgoss D., Hogg N., Schoch E., Endre Z. Cell survival or death in renal tubular epithelium after ischemia-reperfusion injury. Kidney Int 1999, 56:1299-1304.
29. Spandou E., Tsouchnikas I., Karkavelas G., Dounousi E., Simeonidou C., Guiba-Tziampiri O., et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006, 21:330-336.
30. Katavetin P., Inagi R., Miyata T., Shao J., Sassa R., Adler S., et al. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun 2007, 359:928-934.
31. Scarabelli T.M., Stephanou A., Pasini E., Comini L., Raddino R., Knight R.A., et al. Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ Res 2002, 90:745-748.
32. Esson M.L., Schrier R.W. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002, 137:744-752.
33. Bonventre J.V., Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011, 121:4210-4221.
34. Goldman S.A., Nedergaard M. Erythropoietin strikes a new cord. Nat Med 2002, 8:785-787.
35. Juul S.E., Yachnis A.T., Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998, 52:235-249.
36. Metivier F., Marchais S.J., Guerin A.P., Pannier B., London G.M. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000, 15(Suppl. 3):14-18.
37. Kinsey G.R. Macrophage dynamics in AKI to CKD progression. J Am Soc Nephrol 2014, 25:209-211.
38. Duffield J.S. Macrophages in kidney repair and regeneration. J Am Soc Nephrol 2011, 22:199-201.
39. Denby L., Ramdas V., McBride M.W., Wang J., Robinson H., McClure J., et al. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am J Pathol 2011, 179:661-672.
40. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012, 4:121ra18.
41. Denby L., Ramdas V., Lu R., Conway B.R., Grant J.S., Dickinson B., et al. MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol 2014, 25:65-80.
42. McCormick R.I., Blick C., Ragoussis J., Schoedel J., Mole D.R., Young A.C., et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013, 108:1133-1142.
43. Rane S., He M., Sayed D., Vashistha H., Malhotra A., Sadoshima J., et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 104:879-886.